April 30th 2024
Safety findings highlight no severe adverse effects or dose-limiting toxicities with the rintatolimod combination in late-stage pancreatic cancer.
February 16th 2024
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Therapeutic Implications of Molecular Subtyping for Pancreatic Cancer
March 15th 2017In this article, we review seminal articles that have evaluated the molecular architecture of pancreatic cancer. We compare the methods used and the molecular subtypes defined, and assess the predominant subgroups in order to better understand which therapies may improve patient outcomes.
ACR Appropriateness Criteria® Borderline and Unresectable Pancreas Cancer
These guidelines review the use of radiation, chemotherapy, and surgery in borderline and unresectable pancreas cancer. Radiation technique, dose, and targets were evaluated, as was the recommended chemotherapy, administered either alone or concurrently with radiation. This report will aid clinicians in determining guidelines for the optimal treatment of borderline and unresectable pancreatic cancer.
Genomic Analysis Yields Four Subtypes of Pancreatic Cancer
March 9th 2016An integrated genomic analysis has found that pancreatic cancer can be divided into four specific subtypes based on molecular characteristics. This division could help guide treatment decisions and future research avenues into this difficult malignancy.
Race, Geography Associated With Resection Rates in Pancreatic Cancer
November 24th 2015A retrospective cohort study showed that socioeconomic variables including race, marital status, insurance status, and geography are associated with rates of resection for early-stage pancreatic cancer. Most of these factors, however, were not associated with survival following resection.
Current Standards and Novel Treatment Options for Metastatic Pancreatic Adenocarcinoma
November 16th 2015This article reviews the current treatment paradigms for metastatic disease, focusing on ways to ameliorate symptoms and lengthen survival. We then summarize recent advances in our understanding of the molecular and cellular aspects of pancreatic cancer.
Systemic Therapy of Pancreatic Cancer: Better Science, Faster Progress
November 15th 2015The ultimate benefit to patients will come from a demonstration of clinically worthwhile benefits of new drugs that have been tested in well-designed and adequately powered clinical trials performed in an expedited fashion.
FDA Approves New Treatment for Metastatic Pancreatic Cancer
October 23rd 2015The FDA has approved the combination of irinotecan liposome injection plus 5-fluorouracil and leucovorin for the treatment of metastatic pancreatic cancer in patients who previously progressed on gemcitabine-based chemotherapy.
Rigosertib/Gemcitabine Combo Failed to Improve Survival in Pancreatic Cancer
June 20th 2015Patients with treatment-naive metastatic pancreatic cancer assigned to treatment with gemcitabine plus rigosertib did not have any improvement in tumor response or survival compared with treatment with gemcitabine alone.